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bstr t 
Due to its poor capacity for regeneration, the heart is particularly sensitive to the loss of contractile cardiomyocytes. The
onslaught of damage caused by ischaemia and reperfusion, occurring during an acute myocardial infarction and the subse
quent reperfusion therapy, can wipe out upwards of a billion cardiomyocytes. A similar program of cell death can cause the
irreversible loss of neurons in ischaemic stroke. Similar pathways of lethal cell injury can contribute to other pathologies
such as left ventricular dysfunction and heart failure caused by cancer therapy. Consequently, strategies designed to protect
the heart from lethal cell injury have the potential to be applicable across all three pathologies. The investigators meeting at
the 10th Hatter Cardiovascular Institute workshop examined the parallels between ST-segment elevation myocardial infarc
tion (STEMI), ischaemic stroke, and other pathologies that cause the loss of cardiomyocytes including cancer therapeutic
cardiotoxicity. They examined the prospects for protection by remote ischaemic conditioning (RIC) in each scenario, and
evaluated impasses and novel opportunities for cellular protection, with the future landscape for RIC in the clinical setting
to be determined by the outcome of the large ERIC-PPCI/CONDI2 study. It was agreed that the way forward must include
measures to improve experimental methodologies, such that they better reect the clinical scenario and to judiciously select
combinations of therapies targeting specic pathways of cellular death and injury.
KeywordsAnthracycline cardiotoxicity• Cardioprotection• Ischaemic stroke• Myocardial ischaemia• Neuroprotection• 
Reperfusion
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Unlike some organs that readily regenerate following
injury, the adult heart lacks meaningful quantities of
endogenous stem cells able to regenerate cardiomyocytes
[70]when a cardiomyocyte is lost, it is gone forever. It
is, therefore, imperative to preserve the ones we have. In
most cases, the heart endures extraordinarily well, con
tinuing to function for upwards of 70years or more with
exactly the same cardiomyocytes it started with. However,
anST-segmentelevationmyocardialinfarction (STEMI)
causes an onslaught of damage that can wipe out over a
billion cardiomyocytes [77]. Of patients who reach the
hospital and are treated with optimal therapy,>10% will
die within 1year, and many of those who survive will go
on to develop heart failure as a consequence of the initial
infarct [53, 82]. Over the past 25years, the creation of an
emergency care infrastructure enabling rapid myocardial
reperfusion has greatly improved clinical outcomes [90]. 
Unfortunately, in many countries, the reward available
from further logistical improvements in the implementa
tion of this intervention appears to have reached its prac
tical limit. For example, in the recent SWEDE HEART
study, despite an impressive decrease in the numbers of
deaths following STEMI, made after the introduction of
emergency coronary care and the implementation of rep
erfusion therapy, 1-year mortality has remained stubbornly
high at~15% [95].
Like the heart, the adult brain has extremely limited
capacity to make new cells, and acute obstruction of a
conduit artery causes the irreversible loss of cellsa typi
cal ischaemic stroke causes the loss of~1 billion neurons
[87]. Stroke causes 9% of all deaths making it the second
leading cause of death and one of the most costly and
devastating clinical syndromes in the world [30]. Approxi
mately 20% of strokes are caused by intracerebral haemor
rhage, while the other~80% are classied as ischaemic.
With the discovery of thrombolysis, reperfusion therapy
became an option for the treatment of ischaemic stroke.
More recently, the introduction of mechanical thrombec
tomy has brought about a paradigm shift in the optimal
management of ischaemic stroke patients, in particular
those with large vessel occlusion who had had poor reca
nalization rates with thrombolysis [18]. Endovascular
recanalization results in rapid restoration of blood ow
to the ischaemic cerebrum with the promise of improving
neurological salvage and functional outcome. The sequelae
of reperfusion for stroke are similar to those seen during
primary percutaneous coronary intervention for STEMI
[58]. Importantly, in both the brain [35] and myocardium
[58], early reperfusion is the only therapy that is proven
to limit infarct size in patients. However, a substantial
number of stroke patients who receive thrombolysis and/
or thrombectomy in the acute phase never fully recover
[35]. This highlights the need to develop new adjunctive
neuroprotective treatment strategies alongside reperfusion
therapy.
Another of the major killers worldwide is cancer, which
aectsmorethanoneinthreepeopleintheirlifetime[74 ]. 
Anthracyclines such as doxorubicin are highly eective
and commonly used chemotherapeutic agents, but are
restricted by dose-limiting cardiotoxicity [74]. Although
the incidence of anthracycline-induced cardiomyopathy
has declined with contemporary dosing regimens, a sig
nicant number of patients develop left ventricular dys
function and heart failure. The exact proportion of patients
ected is dicult to ascertain due primarily to methodo
logical issues, but has been estimated to be in the range of
326% [14]. The cause of myocardial injury is multifari
ous, but is believed to include oxidative stress, inhibition
of topoisomerase II , mitochondrial dysfunction, and
decits in cardiomyocyte energy production, which lead
to diuse cardiomyocyte death [14, 37, 38, 74]. Although
discussion focussed on anthracyclines, other types of can
cer therapy such as HER2 inhibitors can cause similar car
diac injury leading to heart failure [24,  97].
In all three elds mentioned above, and discussed dur
ing this workshop, discoveries of protective agents that
are eective in experimental studies have failed to trans
late well to clinical studies in patients. The reasons for
this have been extensively discussed in debates that have
progressed similarly in each of the research domains. In
the eld of cardioprotection, recommendations have been
published includingthosederivingfrom previousHatter
Institute workshops [11, 12, 15, 43, 67]. In neuroprotec
tion, the Stroke Treatment Academic Industry Roundtable
(STAIR) guidelines dened similar standards for optimal
experimental design [34], which have been improved upon
over subsequent years [65, 66]. Recommendations have
also been published for pre-clinical studies of chemother
apy-induced cardiotoxicity and associated assessment of
early subclinical myocardial injury biomarkers such as
microRNAs [72, 86]. Acommon theme in theseguide 
lines is the apparent disconnect between overly simplistic
experimental models using young, healthy animals, and
the complex reality of the clinical scenario [11, 2, 15, 34, 
43, 47, 49, 55, 67, 84].
In view of the above, a key question discussed at the
workshop was whether there is any commonality between
the mechanisms of cell death that occur in these three
pathologies and, if so, whether this knowledge can inform
the development of improved cytoprotective modalities
that are able to improve clinical outcome in patients.
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The same butdierent
Supercially, at least, there are a number of obvious com
monalities between STEMI and ischaemic stroke, which
raise the interesting possibility that protective modalities
successful in one scenario may also be eective in the other
(Table1). On the other hand, there are clearly also specic
dierences that may impede the blanket application of thera
pies across these scenarios (Table1). While cardiomyocyte
death is also integral to cardiotoxicity after cancer chemo
therapy, its similarity to the cell death that occurs during
ischaemiareperfusion is more controversial and will be
discussed later.
Both ischaemic stroke and STEMI are usually caused by
obstruction of a main conduit artery by a blood clot. In the
heart, the clot typically forms in the region, where an athero
sclerotic plaque has ruptured [99]. The resulting hypoperfu
sion in the ischaemic area at risk will lead to cell death if
recanalization does not occur promptly. Some of the area at
risk will be salvaged by reperfusion, and its eectiveness can
be further improved by interventions such as ischaemic pre
or post-conditioning [31, 41, 54]. In the brain, thromboem
bolic stroke is more common, but up to 40% of all ischaemic
strokes are of unknown aetiology [30]. In ischaemic stroke,
there may be a zone of non-functioning but viable tissue
that has the potential to recover its function if blood ow
can be restored, for example, by therapeutic intervention.
This region is referred to as the ischaemic penumbra [5 ].
At a cellular level, the response to ischaemia is broadly
similar in the heart and brain [57]. Since neurons and car
diomyocytes rely on high rates of oxidative phosphoryla
tion for the production of ATP, in the absence of oxygen,
ATP is rapidly depleted. While cells can survive on ATP
produced by glycolysis for a short time, eventually, this
decreases to levels that are insucient to maintain essential
ion homeostasis, and Ca2+ begins to ood in and overload
the cells. Reperfusion restores the essential ow of oxygen
and nutrients to starved cells [21]. In both heart and brain,
the mitochondria are the source of their own demise, as rapid
re-activation of the electron transport chain results in a burst
of superoxide production, which conspires with calcium to
increase opening of the mitochondrial permeability transi
tion pores (MPTP) [8, 28, 71, 89]. Above a critical thresh
old, damage is irreversible and catastrophic injury results in
cell death, primarily by necrosis/oncosis. Other types of cell
death such as necroptosis are also involved [69, 93]. Apop
tosis is important in the brain, but its role in the reperfused
heart is more controversial [17, 59, 62, 68]. Although the
mechanisms of cellular injury caused by ischaemiareper
fusion are very similar in the heart and brain, the brain is
uniquely sensitive to damage caused by glutamate released
from depolarized cells which causes glutamate excitotoxic
ity [45,  83].
However, infarction causes more than just the death of
cardiomyocytes or neurons. The vasculature is essential not
just for delivery of oxygenated blood, but for insulating the
parenchyma from blood constituents and excessive liquid.
This is particularly important in the brain, where energy
depletion and bloodbrain-barrier dysfunction can result in
malignant oedema, a major cause of death following stroke
[9]. Disruption of the neurovascular unit (which comprises
endothelial cells, pericytes, vascular smooth muscle cells,
astrocytes,microglia,andneurons)mayalsoleadtofurther
neuronal death. The vessels of the heart have an analogous,
non-fenestrated endothelial cell layer, which is in some sense
a blood-heart barrier. Damage to the cardiac endothelium
can also result in oedema [48].
The debate about the significance of the differences
between brain and heart, and their impacts on protection, led
to the question of what is the most important experimental
outcome. In experimental myocardial infarction studies, the
gold standard and primary measure of outcome is infarct
size (as a percentage of area at risk) [15], which predicts
progression to heart failure in patients [94]. However, in the
brain, infarct location is far more important than infarct size
per se in determining functional outcome. For this reason,
both neuroscore and infarct size should be considered in
neuroprotection studies. The use of multiparametric MRI
to assess per-occlusion and follow-up brain damage has the
potential to improve translation by providing the same imag
ing endpoints in both the pre-clinical and clinical settings
[19]. One of the greatest fears for the neurologist ministering
to a patient with ischaemic stroke is haemorrhagic transfor
mation [9, 30], whereas in the heart, haemorrhage is not a
prime concern.
In both brain and heart, the degree of injury is highly
dependent on the duration, extent and severity of ischaemia
[51, 76]. The sole therapy available for each is reperfusion.
The kinetics of reperfusion may be very dierent in patients
treated with thrombolysis vs PCI or mechanical thrombec
tomy. Most experimental models, however, study reperfu
sion as an acute event. Rodent models of thromboembolic
roke amenable to thrombolysis do exist, but require more
animals per group due to inherently greater experimental
variability (see, for example, [102]). Reperfusion injury
has been well studied in the heart, and is also thought to
occur in the brain [4, 7, 68, 79, 83]. As such, targeting rep
erfusion injury should be considered an eective means of
developing additional adjunctive therapies in patients with
acute ischaemic stroke [62, 88]. Another key determinant
of ischaemiareperfusion injury in both heart and brain is
the extent of collateralization. In the brain, some functional
redundancy of blood supply is naturally provided by the cir
cle of Willis (Fig.1)although the precise anatomy of these
vessels can be quite variable between patients. Furthermore,
the functionality of secondary collateral pathways such as
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Penumbra Infarct 
Fig. In the brain, middle cerebral artery occlusion results in a gra
dient of reduction in cerebral blood ow from the ischaemic core 
(red) through the penumbra and oligaemia (blue) to normally per
fused cortex (grey). No reow may also occur from 5 to 10min. In 
leptomeningeal anastomoses is believed to be a main deter
minant of stroke outcome [39].
Even after successful recanalization of the occluded ves
sel, reperfusion at the level of the tissue may be limiteda
situation called no reow. No reow occurs in both the 
heart and the brain but with very dierent kinetics and a par
tially distinct mechanism [48, 52, 64]. No reow can occur 
within 510min of ischaemia in the brain [3], and may, 
therefore, contribute to neuronal death, whereas in the heart
it only occurs after 30+min and its contribution to cell death
is less clear [64]. The fact that the brain is conned within a
rigid skull may contribute to the dierences in the manifes
tation of no reow [64]. In the brain, perfusion decits occur
in a gradient from the infarct through to an oligaemic region 
of mildly reduced blood ow, via an ischaemic penumbra of 
potentially salvageable tissue.
With regard to the above discussion, it was unanimously
agreed that experimentally; in both heart and brain, it is 
crucial to accurately determine the volume of tissue that is 
ischaemic and, therefore, at risk of infarction. While in the 
heart, this can be readily achieved by Evans blue staining 
exvivo, or the use of microspheres, in the brain this is not 
a trivial matter due to its extensive collateralization. The 
 
 
 
 
 
 
 
Area 
At No Infarct 
Risk reflow 
the heart, occlusion of the LAD followed by reperfusion results in an 
ischaemia area risk in which a transmural infarct slowly develops, fol
lowed by the appearance of a zone of no reow within the infarct
clinical method of estimating the ischaemic penumbra by 
measuring the per-occlusion perfusion/diusion mismatch 
by MRI can also be applied in animal models of transient 
stroke (Fig.2) [29]. Thus, MRI has the potential to improve
the overall methodology of pre-clinical neuroprotection 
studies, with the advantage that it can also be used to provide
a measure of infarct size that matches well with tetrazolium
chloride staining [20].
The use of rodent models in cardioprotection and neu
roprotection has limitations. There are clearly major dier
ences between lissencephalic brains of small mammals and
gyrencephalic brains of larger species, which lead to the 
recommendation to conrm results in rabbits or non-human
primates [66]. Similar reasoning is frequently used to sup
port the need for cardioprotection studies in pigs [56] prior
to clinical studies, although one might question whether 
healthy pig hearts, with their low native collateralization, are
generally the ideal model of patients with coronary artery 
disease (CAD), who may or may not be highly collateralized.
One factor specic to MI, which may have contributed 
to the poor translation of cardioprotection between animal 
models of ischaemia-reperfusion injury and patients, is 
the clinical use of P2Y12 platelet inhibitors, which exhibit 
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Magnetic Perfusion-weighted Diffusion-weighted 
resonance image (PWI) image (DWI) 
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ig. MRI images of a rat subject to middle cerebral artery (MCA) 
occlusion and reperfusion, illustrating recruitment of the ischae
mic penumbra in the infarct. The top panels conrm the complete 
occlusion of the MCA and show the perfusion-weighted and diu
coagulation-independent cardioprotection in their own right
[12, 23]. Although nearly all STEMI patients receive such
medication, platelet inhibitors are not used at the time of
recanalization in stroke for fear of causing haemorrhagic
conversion. Thus, this potential confounding factor is only
relevant to STEMI and not to ischaemic stroke.
At another level, several parallels can be drawn between
the mechanism of cardiac injury caused by STEMI and
anthracycline cardiotoxicity, including the role of oxidative
stress, mitochondrial damage, and cardiomyocyte death [37, 
38, 74]. It was noted that current clinical trials aim to treat
heartfailureafterithasbeendetected,butnottopreventthe
causewhich is cardiomyocyte death. New experimental
studies are needed of agents that are better able to protect the
cardiomyocytes from anthracycline toxicity, with the added
condition that they must absolutely not reduce the ecacy
of the cancer treatment [74].
Cyto-protectionthe present situation
A number of issues were discussed at this workshop that are 
relevant to each of the three pathological scenarios described
above. It was agreed that one of the most promising forms of
cyto-protection is the phenomenon of remote ischaemic con
ditioning (RIC) [40, 46, 50]. RIC is a highly robust method
of reducing myocardial infarct size in animal models [16] 
as well as in proof of concept clinical studies [51]. One out
standing issue that was discussed at the workshop relates to
the RIC protocol, which remains to be optimized in humans.
Time 0 h  
Time 24h 
sion-weighted images, which when combined reveal the ischaemic 
penumbra. In the lower panel, after 24h part of the penumbra has 
been recruited into the area of infarct, and brain swelling has caused a 
quantiable shift of the midline
Despite eorts made in this regard in animal models [16, 
60],clinicaltrialstypicallyuseaprotocolof3or4cycles
of 5min upper limb ischaemia (maximum 200mmHg) fol
lowed by 5min reperfusion, which was eective in phase
1 trials [51]. Yet, no phase II trials have been performed.
RIC has repeatedly been shown to reduce the release of
cell-death biomarkers such as troponin or creatine kinase
in pilot studies of STEMI [51]. Interestingly, there are also
indications of improvements in long-term clinical outcome
with signicant reductions in major adverse cardiac and
cerebrovascular events (MACCE) [91] and mortality [36]. 
It was felt that STEMI remained the most important target
for cardioprotection from RIC or pharmacological therapy.
It was debated whether other settings such as CABG, which
has had two neutral clinical outcome studies [42, 75] should
still be considered amenable for cardioprotection [63, 96].
Results are eagerly awaited from the ERIC-PPCI/
CONDI-2 study investigating the eect of RIC on clinical
outcomes in patients presenting with an STEMI undergo
ing primary percutaneous coronary intervention [44]. All
participantsattheworkshopagreedthattheoutcomeofthis
pivotal study will determine the direction that cardiovascular
research will take for the next decade. However, irrespective
of the results of this study, what is true for the heart might
not be true for the brain.
Evidence was shown that ischaemic preconditioning
(IPC) may be able to protect cardiac cells from anthracy
cline toxicity, while not increasing the survival of cancer
cells [73]. A clinical study is currently being undertaken to
Basic Research in Car diology (2018) 113:43
1 3
P  
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
       
 
 
        
 
 
 
  
 
 
 
 
C  
 
  
  
 
 
Ref enc
    
          
      
ge 7 of 11 43 
assess the ecacy of RIC in patients receiving doxorubicin
for cancer therapy [22].
Derek Yellon presented data obtained using a new experi
mental rat model that could potentially be used to evalu
ate cardioprotection on a background of agents commonly
administered to STEMI patients. These preliminary studies
were designed to ascertain if it is possible to obtain an ani
mal model more representative of patients and included the
use of an anticoagulant, an analgesic and antiplatelet agent.
The participants agreed that this represented a promising
rst step to overcoming some of the translational hurdles
that have impaired translation.
The prevalence of obesity and diabetes is steadily increas
ing and is predicted to cause the incidence of myocardial
infarction and strokes to soar in the next two decades. Dia
betes and other co-morbidities worsen the outcome from
both STEMI and ischaemic stroke, and also impair cardio
protectiveandneuroprotectivestrategiesinanimalmodels
[32, 67, 80]. Given the above, Derek Yellon proposed that a
multi-targeted strategy would be required to protect the heart
or brain from IR injury as a way forward [25,  85].
However, despite the overall negative impact of diabetes
on the cardiovascular system, it has perhaps been indirectly
responsible for shining a glimmer of light onto the eld
of cardioprotection. There was an interesting discussion
about the cardioprotective benet that has now been seen
in three, separate, large clinical trials of antidiabetic thera
pies, namely, the SGLT2 inhibitors [2, 101]. These results
from recent large clinical studies show conclusively that car
dioprotection is a viable option. What is now required is to
ascertain the mechanism by which these agents elicit their
protection [13].
The way forward
A succinct set of ten guidelines were put forward at the pre
vious Hatter meeting [12]. Many of these proposals have
been incorporated into subsequent statements and recom
mendations. In particular, it was felt that, given the multiple
redundancies in cell death pathways, targeting of a single
pathway may be unable to aord sucient protection for
clinical benet. As such, it is important to investigate all the
forms of cell death to achieve maximum protection.
To increase the potency of protection and inhibit alter
native deathpathways, amulti-targettherapeutic approach
may be necessary to achieve a clinically meaningful benet
[25].Additivecardioprotectionhasbeenseen,e.g.,with
the caspase 1 inhibitor VX-765 administered at reperfu
sion in P2Y12 receptor antagonist-treated rats [6]. Com
bination therapy may also have the potential to protect
against acute ischaemic stroke, but this important concept
remains unproven in this setting [81, 100]. To design a
rational, multi-targeted approach, it is important to know
the mechanisms and perform accurate doseresponse experi
ments. One promising avenue of research is exosomes.
These are nanoparticles that have been shown to be cardio
protective in animal models, which may be able to target
multiple pathways via their protein and miRNA cargo [26, 
27, 92, 98]. However, many questions remain, including the
real identity of their cellular target in the heart, and optimal
methods for their purication and delivery [27].
All participants recognized that a better methodology will
be required in order to close the translational gap. Ulti
mately, two types of animal models are useful: one which
is simplistic, conceptual and reductionist, which can inform
about mechanisms and a second type of model that is com
plex, real-world, clinical, translational, and pragmatic, which
can be used as a test bed towards clinical translation.
In line with the previous recommendations, a system is
urgentlyneeded to enabletheconductofmulti-centreanimal
trials, much like the CAESAR network previously estab
lished inUSA[ 61],or theMULTIPARTnetworkforneu 
roprotection [1]. Interestingly, such a multi-centre, blinded,
randomized, controlled experimental infarct study was previ
ously used successfully in the year 2000 to demonstrate that
anadenosineA1agonistatreperfusionwascardioprotective
when administered prior to coronary occlusion in rabbits,
but not when administered immediately prior to reperfusion
[10]. All future studies should follow as closely as possible
the appropriate guidelines [12, 15, 34, 65 67, 78] on eec
tive translational research.
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